While YAP signaling clearly supported the proliferation of RNF43-mutant pancreatic cancer (Figure 2E), the sgRNAs targeting YAP suppressors SAV1 or LATS1 were not further enriched by ETC-159 treatment (Figure 2F), suggesting that YAP activation could not bypass Wnt dependency in RNF43-mutant pancreatic cancer. The gene discussed is LATS1; the disease is pancreatic neoplasm.